NeoGenomics Expands Oncology Testing Reach In The Northeast With Acquisition Of Pathline

 NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics’ commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country.

https://www.businesswire.com/news/home/20250310904423/en/NeoGenomics-Expands-Oncology-Testing-Reach-in-the-Northeast-with-Acquisition-of-Pathline